Prepared Highlights
- Q1 2026 revenue of $1.8 billion, core growth 4.4%, within guidance range (prepared)
- Operating margin 24.6%, in line with expectations; EPS $1.36, within expectations (CFO)
- Segment: ACG grew 6% (consumables high-single-digit); AMG grew 4% (spectroscopy double-digit); LDG grew 3% (weather impact, academia/government softness) (CFO)
- Pharma growth 7%; GLP-1 growth 50%; CDMO business low-double-digit growth (CEO)
- Chemicals & advanced materials (CAM) grew 9% (above expectations), advanced materials >20% (CEO)
- Diagnostics & clinical grew 7%; food declined 4%; academia/government down 8%; environmental/forensics flat (CEO)
- Operating cash flow $268 million; CapEx $93 million; share buybacks $152 million; dividends $72 million (CFO)
- Net leverage ratio 0.8 turns; full-year operating cash flow range unchanged at $1.6–1.7 billion (CFO)
- Ignite Operating System: delivered ~200 bps pricing in Q1; digital orders grew >2× overall order book (CEO)
- Full-year guidance: core growth 4–6%; EPS $5.90–$6.04 (raised by $0.04 due to favorable FX); revenue $7.3–7.5 billion (reported); tax rate 14.5% (CFO)
- Q2 guidance: core growth ~4–5.5%; EPS $1.39–$1.42; reported revenue $1.79–1.82 billion (CFO)
Selected Management Quotes
- "It was a solid start to the year with the Agilent team executing well in a generally improving, albeit dynamic market environment." — CEO
- "Altura has more than doubled our biocolumn growth to over 30%, a testament to Altura's compelling performance." — CEO
- "We are confident we will see improved earnings growth through the remainder of the year, driven by improving volumes and easier tariff and performance-based pay compares." — CFO
- "We continue to expect to deliver 75 basis points of operating margin expansion at the midpoint." — CFO
- "Even with these strong results, the upside from pharma reshoring has yet to impact our numbers." — CEO
Prepared Metrics
| Metric | Value | Speaker/Context |
|---|
| Q1 Revenue | $1.8B | prepared |
| Core Growth (Q1) | 4.4% | CEO |
| Operating Margin (Q1) | 24.6% | CFO |
| EPS (Q1) | $1.36 | CFO |
| Gross Margin (Q1) | 53.7% | CFO |
| ACG Growth (Q1) | 6% | CFO |
| AMG Growth (Q1) | 4% | CFO |
| LDG Growth (Q1) | 3% | CFO |
| Pharma Growth (Q1) | 7% | CEO |
| CAM Growth (Q1) | 9% | CEO |
| Diagnostics & Clinical Growth (Q1) | 7% | CEO |
| Food Growth (Q1) | -4% | CEO |
| Academia/Government Growth (Q1) | -8% | CEO |
| GLP-1 Growth (Q1) | 50% | CEO |
| China Growth (Q1) | 6% | CFO |
| Rest of Asia Growth (Q1) | 13% | CFO |
| Americas Growth (Q1) | 1% | CFO |
| Europe Growth (Q1) | 4% | CFO |
| Operating Cash Flow (Q1) | $268M | CFO |
| CapEx (Q1) | $93M | CFO |
| Share Repurchases (Q1) | $152M | CFO |
| Dividends (Q1) | $72M | CFO |
| Full-Year Core Growth Guide | 4–6% | CFO |
| Full-Year EPS Guide | $5.90–$6.04 | CFO |
| Full-Year Reported Revenue Guide | $7.3–7.5B | CFO |
| Q2 Core Growth Guide | ~4–5.5% | CFO |
| Q2 EPS Guide | $1.39–$1.42 | CFO |
| Q2 Reported Revenue Guide | $1.79–1.82B | CFO |
| Full-Year Tax Rate | 14.5% | CFO |
| Full-Year CapEx | ~$500M | CFO |
| Full-Year Op. Cash Flow | $1.6–1.7B | CFO |
Q&A Batch (1-5 of 5)
Company: A (A)
Call: Q1 2026 (2026-02-25 16:30:00)
Q1 — Jack Melick
- Topic: 暴风雪对收入和利润率的影响，以及全年利润率提升节奏
- Key points:
- 暴风雪造成约1000万美元收入损失，大部分已收回，仅少量服务类收入延迟
- 对利润率影响极小，Q1实际利润率可视为真实表现的合理代理
- 全年仍指引75个基点的利润率扩张，Q2同比改善50个基点，下半年加速（由定价、销量、Ignite节约驱动，部分被绩效薪酬和关税抵消）
- Mgmt stance: 中性偏积极 – 已恢复大部分收入，利润率改善路径清晰，且关税在下半年完全抵消
Q2 — Vijay Kumar
- Topic: 上半年与下半年收入增长驱动，以及关税假设
- Key points:
- 上半年收入约49%的下半年占比，下半年约51%（增长幅度从不到5%提升至超过5%）
- 增长驱动力：GLP-1药物、替换周期、Infinity III双位数增长、先进材料（半导体）20%增长
- 若全球最低关税15%落实，不会改变当前指引；已采取无遗憾措施（制造靠近客户、定价与附加费）
- Mgmt stance: 中性 – 增长动力可见，但关税动态不确定；公司已做好准备应对变化
Q3 — Douglas Schenkel
- Topic: 资本设备需求月度趋势与并购意愿
- Key points:
- 需求稳定：Q1强劲的预算流出、1月受欧洲干扰和天气影响但漏斗持续增长；没看到CapEx恶化
- 资本配置优先级不变：内部创新投资 > M&A > 战略产能扩张，同时通过股息和回购回报股东
- 转型并购门槛很高，不需要变革性交易来实现增长目标
- Mgmt stance: 中性 – 有机业务良好，CapEx环境稳定；并购仅考虑高回报机会，不急于大额交易
Q4 — Patrick Donnelly
- Topic: LDG板块疲软原因及CDMO表现
- Key points:
- LDG增长3%，低于中高个位数预期，受天气及学术/政府市场疲软（
Q&A Batch (6-10 of 11)
Q6 — Daniel Leonard
- Topic: 原子光谱业务增长驱动与制药市场细分表现
- Key points:
- 原子光谱业务增长源于内存短缺、全球晶圆厂回流（印度、亚洲、美洲）以及AI下游化学需求；化学品业务占CAM业务约2/3，先进材料占1/3。
- 小分子业务实现中个位数增长，亚洲领跑（低双位数增长）；GLP-1相关业务增长强劲：分析实验室GLP-1收入增长50%（占7%），CDMO侧增长120%。
- 单四极杆产品（QA/QC核心）增长40%，替换周期动能强劲。
- Mgmt stance: 乐观——管理层认为原子光谱和GLP-1业务将持续增长，全年动能强劲。
Q7 — Michael Ryskin
- Topic: 季度业绩波动（天气影响1000万美元）与全年核心指引维持
- Key points:
- 季度末最后3天因风暴未能确认1000万美元收入，该收入已于次周一确认；关键市场（制药、CAM、诊断）表现良好，仅小型市场有微小偏差。
- 全年核心指引维持不变，终端市场预期与之前一致；NIH仅占公司资金的1%，影响极小。
- Infinity III产品增长约为同行2倍，推动替换周期。
- Mgmt stance: 乐观——管理层对全年剩余时间持积极态度，认为关键市场动能可抵消短期波动。
Q8 — Jack Meehan
- Topic: M&A整合能力（Ignite系统）与诊断资产兴趣
- Key points:
- Ignite系统通过跨职能协调提升整合效率，已成功用于整合BIOVECTRA；关税管理也依赖该跨职能方法。
- 资本配置聚焦于增加服务和经常性收入占比（软件、自动化、系统内容）；诊断业务Q1增长7%，病理学为长期中个位数增长市场。
- 诊断资产未被排除，但需符合“增加经常性收入”和“有获胜权”的战略标准。
- Mgmt stance: 中性偏乐观——管理层强调Ignite系统提升整合信心，但诊断资产仅作为潜在选项之一，需匹配战略。
Q9 — Puneet Souda
- Topic: GLP-1业务利用率、Train C/D产能爬坡及小型生物技术公司影响
- Key points:
- 订单积压强劲，FY‘26展望持续爬坡；Train C和D产能上线及时，2026年已订满，2027年正接受更大商业批次订单。
- 稳态下专业CDMO业务利润率将高于公司整体营业利润率；2027年Train C/D爬坡将带来负面利润率影响，但将通过Ignite等其他活动抵消。
- 小型和中型生物技术公司融资环境改善（1月总融资约110亿美元，为2年高点），但尚未看到实质性支出增长；公司对该领域敞口较小。
- Mgmt stance: 乐观——管理层对CDMO产能利用率和长期利润率有信心，但小型生物技术公司复苏仍需时间。
Q10 — Brandon Couillard
- Topic: 中国6%增长驱动因素与AMG市场区域表现
- Key points:
- 中国Q1增长6%，略好于预期，部分受春节前支出推动；去年GACC刺激业务强劲，今年较小，公司赢得约30%份额；全年中国业务预计为3亿美元/季度。
- 中国长期增长预期为中高个位数（非10年前的双位数）；公司在中国制造和商业团队贴近客户，且中国“十五五”规划（AI、医疗、绿色、PFAS法规）与公司优势契合。
- AMG市场疲软主要来自美洲；NIH预算持平或微增，15%间接成本上限被阻止，但客户仍对大额投资犹豫；欧洲预计更稳定，但为前瞻性判断。
- Mgmt stance: 乐观——管理层对中国长期增长和自身定位有信心，但美洲学术和政府市场短期仍存在不确定性。
Q&A Batch (11-11 of 11)
Q11 — Casey Woodring
- Topic: LC/MS growth phasing and enterprise service contract financial impact
- Key points:
- LC grew high single digits in Q1, with particular strength in China and APAC; Infinity III replacement cycle still relatively early-mid.
- LC/MS was in line with Q1 expectations, coming off tough sequential and YoY compares; Pro iQ grew 40%, with exceptional adoption.
- Enterprise service agreements (marquee wins in ACG) create a flywheel: higher consumables attach rate, higher services attach rate, early warning on replacement cycles, and competitive displacement opportunities.
- Mgmt stance: Bullish — management highlights share gains (positive win/loss rates, industry data), strong innovation pipeline (Altura columns, broader LC/MS pipeline), and compounding growth from enterprise services.